

Walpole

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	26	25.7	101.1	(66.0-148.1)	Male	27	17.2	157.4	(103.7-229.0)
Female	9	10.1	89.0	(40.6-168.9)	Female	14	13.8	101.5	(55.5-170.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	5.0	nc	(nc-nc)	Male	2	4.3	nc	(nc-nc)
Female	5	4.3	116.1	(37.4-270.9)	Female	3	3.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	14	14.9	93.8	(51.3-157.5)
Female	113	101.5	111.3	(91.7-133.8)	Female	12	12.9	92.9	(47.9-162.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	3.7	135.8	(43.8-316.9)	Male	10	10.6	94.1	(45.1-173.1)
<u>Colon / Rectum</u>					Female	1	5.1	nc	(nc-nc)
Male	31	31.3	99.0	(67.2-140.5)	<u>Ovary</u>				
Female	29	33.9	85.5	(57.3-122.8)	Female	12	9.8	122.4	(63.2-213.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	6.9	nc	(nc-nc)	Male	7	8.4	83.6	(33.5-172.3)
Female	0	2.1	nc	(nc-nc)	Female	6	9.7	61.9	(22.6-134.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.1	nc	(nc-nc)	Male	95	100.9	94.1	(76.2-115.1)
Female	1	1.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	6.0	83.2	(26.8-194.1)
Male	23	14.3	161.2	(102.2-242.0)	Female	2	3.9	nc	(nc-nc)
Female	5	8.5	58.6	(18.9-136.8)	<u>Testis</u>				
<u>Larynx</u>					Male	6	3.3	182.9	(66.8-398.2)
Male	6	4.0	148.8	(54.3-323.8)	<u>Thyroid</u>				
Female	0	1.2	nc	(nc-nc)	Male	8	5.6	142.2	(61.2-280.2)
<u>Leukemia</u>					Female	22	16.9	130.0	(81.4-196.8)
Male	4	9.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	7.5	nc	(nc-nc)	Female	24	23.1	103.8	(66.5-154.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	7.7	78.1	(28.5-169.9)	Male	356	352.6	101.0	(90.7-112.0)
Female	2	2.8	nc	(nc-nc)	Female	331	356.1	92.9	(83.2-103.5)
<u>Lung and Bronchus</u>									
Male	52	48.0	108.3	(80.9-142.0)					
Female	44	51.3	85.8	(62.4-115.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Waltham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	58	50.4	115.0	(87.4-148.7)	Male	32	36.7	87.1	(59.6-123.0)
Female	27	22.1	122.3	(80.6-177.9)	Female	27	32.0	84.3	(55.6-122.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	11.3	61.7	(24.7-127.1)	Male	12	8.7	137.3	(70.9-239.8)
Female	11	9.9	110.6	(55.1-197.9)	Female	5	7.9	63.3	(20.4-147.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.5	nc	(nc-nc)	Male	36	32.0	112.5	(78.8-155.7)
Female	242	216.7	111.7	(98.0-126.7)	Female	26	28.5	91.2	(59.6-133.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	8.8	91.3	(39.3-179.9)	Male	31	23.1	134.1	(91.1-190.4)
<u>Colon / Rectum</u>					Female	9	11.1	81.0	(37.0-153.8)
Male	58	64.0	90.6	(68.8-117.1)	<u>Ovary</u>				
Female	77	73.0	105.5	(83.2-131.8)	Female	30	21.5	139.7	(94.2-199.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	13	14.1	92.1	(49.0-157.4)	Male	23	16.7	137.8	(87.4-206.8)
Female	8	4.5	177.0	(76.2-348.7)	Female	28	21.0	133.5	(88.7-192.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	6.5	nc	(nc-nc)	Male	193	206.4	93.5	(80.8-107.7)
Female	7	4.9	142.8	(57.2-294.3)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	16	12.1	132.2	(75.5-214.6)
Male	28	30.0	93.3	(62.0-134.8)	Female	9	8.5	106.2	(48.5-201.7)
Female	14	18.5	75.7	(41.3-127.0)	<u>Testis</u>				
<u>Larynx</u>					Male	10	11.6	86.4	(41.3-158.9)
Male	6	8.3	72.5	(26.5-157.8)	<u>Thyroid</u>				
Female	2	2.6	nc	(nc-nc)	Male	16	13.8	116.2	(66.4-188.7)
<u>Leukemia</u>					Female	37	41.2	89.7	(63.2-123.7)
Male	13	20.0	65.0	(34.6-111.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	21	16.5	127.0	(78.6-194.1)	Female	39	49.7	78.5	(55.8-107.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	12	16.2	74.2	(38.3-129.7)	Male	730	732.0	99.7	(92.6-107.2)
Female	6	6.0	100.5	(36.7-218.8)	Female	807	778.9	103.6	(96.6-111.0)
<u>Lung and Bronchus</u>									
Male	121	94.3	128.3	(106.5-153.4)					
Female	109	110.9	98.2	(80.7-118.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ware

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	11.5	87.0	(41.6-160.0)	Male	7	7.5	93.6	(37.5-192.9)
Female	4	4.6	nc	(nc-nc)	Female	7	6.1	114.0	(45.7-234.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	2.1	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)	Female	3	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	6.6	nc	(nc-nc)
Female	27	45.1	59.9	(39.5-87.2)	Female	4	5.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.6	nc	(nc-nc)	Male	6	4.6	131.4	(48.0-285.9)
<u>Colon / Rectum</u>					Female	2	2.3	nc	(nc-nc)
Male	13	14.1	92.4	(49.1-158.0)	<u>Ovary</u>				
Female	11	15.7	70.3	(35.0-125.8)	Female	3	4.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	3.0	nc	(nc-nc)	Male	4	3.7	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	2	4.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.9	nc	(nc-nc)	Male	34	42.1	80.8	(55.9-112.9)
Female	0	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	2.7	nc	(nc-nc)
Male	3	6.1	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
Female	4	3.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.4	nc	(nc-nc)
Male	3	1.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
<u>Leukemia</u>					Female	4	7.4	nc	(nc-nc)
Male	2	4.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	3.4	nc	(nc-nc)	Female	8	10.2	78.2	(33.7-154.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	3.3	nc	(nc-nc)	Male	133	152.5	87.2	(73.0-103.3)
Female	1	1.2	nc	(nc-nc)	Female	121	159.8	75.7	(62.8-90.5)
<u>Lung and Bronchus</u>									
Male	22	20.7	106.3	(66.6-161.0)					
Female	21	22.7	92.6	(57.3-141.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wareham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	39	28.5	136.8	(97.3-187.0)	Male	9	18.1	49.8	(22.7-94.5)
Female	12	9.5	126.0	(65.0-220.1)	Female	9	13.2	68.0	(31.0-129.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	5.0	nc	(nc-nc)	Male	6	4.7	129.0	(47.1-280.8)
Female	4	4.1	nc	(nc-nc)	Female	1	3.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.8	nc	(nc-nc)	Male	11	15.7	70.1	(35.0-125.5)
Female	90	99.4	90.5	(72.8-111.3)	Female	8	12.3	64.8	(27.9-127.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	3.6	nc	(nc-nc)	Male	12	11.0	108.6	(56.1-189.8)
<u>Colon / Rectum</u>					Female	5	4.9	101.8	(32.8-237.6)
Male	50	34.0	146.9	(109.1-193.7)	<u>Ovary</u>				
Female	33	30.7	107.4	(73.9-150.8)	Female	10	9.5	105.6	(50.5-194.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	12	7.4	161.2	(83.2-281.7)	Male	11	9.2	120.1	(59.9-214.9)
Female	1	2.0	nc	(nc-nc)	Female	15	8.9	168.1	(94.0-277.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.0	nc	(nc-nc)	Male	100	108.6	92.1	(74.9-112.0)
Female	2	1.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	6.6	76.3	(24.6-178.0)
Male	22	14.9	147.2	(92.2-222.9)	Female	1	3.4	nc	(nc-nc)
Female	8	8.3	95.9	(41.3-189.0)	<u>Testis</u>				
<u>Larynx</u>					Male	2	3.1	nc	(nc-nc)
Male	6	4.3	138.0	(50.4-300.5)	<u>Thyroid</u>				
Female	3	1.2	nc	(nc-nc)	Male	4	5.5	nc	(nc-nc)
<u>Leukemia</u>					Female	16	16.6	96.2	(54.9-156.2)
Male	15	10.0	150.0	(83.9-247.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	6.8	117.4	(50.6-231.4)	Female	22	23.3	94.4	(59.2-143.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	11	8.1	135.8	(67.7-243.0)	Male	426	378.4	112.6	(102.1-123.8)
Female	4	2.6	nc	(nc-nc)	Female	356	342.6	103.9	(93.4-115.3)
<u>Lung and Bronchus</u>									
Male	76	52.4	145.0	(114.2-181.5)					
Female	66	50.6	130.4	(100.8-165.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Warren

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	4.9	nc	(nc-nc)	Male	2	3.5	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)	Female	3	3.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.1	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
Female	30	22.9	131.2	(88.5-187.4)	Female	2	2.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.8	nc	(nc-nc)	Male	0	2.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.1	nc	(nc-nc)
Male	5	6.2	80.4	(25.9-187.7)	<u>Ovary</u>				
Female	3	7.0	nc	(nc-nc)	Female	2	2.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.4	nc	(nc-nc)	Male	5	1.6	305.0	(98.3-711.7)
Female	1	0.4	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	14	20.8	67.3	(36.8-112.9)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.2	nc	(nc-nc)
Male	2	3.0	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.8	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<u>Leukemia</u>					Female	5	3.9	127.4	(41.1-297.3)
Male	0	1.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	1.5	nc	(nc-nc)	Female	8	5.1	157.6	(67.9-310.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	1.7	nc	(nc-nc)	Male	50	71.4	70.0	(52.0-92.3)
Female	0	0.6	nc	(nc-nc)	Female	84	77.0	109.1	(87.1-135.1)
<u>Lung and Bronchus</u>									
Male	10	9.3	107.4	(51.4-197.6)					
Female	13	10.7	121.2	(64.5-207.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Warwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	0.8	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	3	2.9	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.7	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	3.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	2	0.5	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.2	nc	(nc-nc)	Male	10	10.9	92.0	(44.0-169.1)
Female	0	0.1	nc	(nc-nc)	Female	10	9.1	109.7	(52.5-201.7)
<u>Lung and Bronchus</u>									
Male	1	1.5	nc	(nc-nc)					
Female	1	1.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Washington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	2.7	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<u>Ovary</u>				
Female	1	0.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	3.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.5	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.2	nc	(nc-nc)	Male	6	9.9	60.8	(22.2-132.3)
Female	0	0.1	nc	(nc-nc)	Female	3	9.0	nc	(nc-nc)
<u>Lung and Bronchus</u>									
Male	0	1.2	nc	(nc-nc)					
Female	0	1.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Watertown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	44	38.3	115.0	(83.5-154.4)	Male	17	24.3	70.0	(40.7-112.1)
Female	12	14.0	85.8	(44.3-149.9)	Female	20	20.0	100.1	(61.1-154.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	6.9	101.7	(40.8-209.6)	Male	5	6.1	81.4	(26.2-190.0)
Female	11	6.1	179.9	(89.7-321.8)	Female	4	5.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.1	nc	(nc-nc)	Male	12	21.2	56.6	(29.2-98.9)
Female	145	137.8	105.2	(88.8-123.8)	Female	22	17.9	122.6	(76.8-185.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	5.5	90.6	(29.2-211.5)	Male	13	14.1	92.5	(49.2-158.1)
<u>Colon / Rectum</u>					Female	7	7.1	99.2	(39.8-204.5)
Male	37	45.8	80.8	(56.9-111.4)	<u>Ovary</u>				
Female	42	46.6	90.1	(65.0-121.8)	Female	12	13.6	88.4	(45.6-154.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	9.4	63.7	(23.3-138.8)	Male	18	12.1	148.3	(87.9-234.4)
Female	4	2.9	nc	(nc-nc)	Female	19	13.3	142.3	(85.7-222.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	3.3	149.9	(48.3-349.8)	Male	125	133.7	93.5	(77.8-111.4)
Female	0	2.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	10	8.8	113.6	(54.4-208.9)
Male	22	19.2	114.4	(71.7-173.2)	Female	6	5.4	111.2	(40.6-242.1)
Female	15	11.7	127.8	(71.4-210.7)	<u>Testis</u>				
<u>Larynx</u>					Male	7	5.9	119.3	(47.8-245.9)
Male	6	5.5	109.8	(40.1-239.1)	<u>Thyroid</u>				
Female	1	1.7	nc	(nc-nc)	Male	9	7.7	116.3	(53.1-220.8)
<u>Leukemia</u>					Female	30	25.7	116.9	(78.8-166.9)
Male	10	13.8	72.3	(34.6-133.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	9	10.3	87.2	(39.8-165.6)	Female	33	31.6	104.3	(71.8-146.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	8	10.2	78.7	(33.9-155.0)	Male	452	494.7	91.4	(83.1-100.2)
Female	5	3.8	131.3	(42.3-306.5)	Female	509	492.9	103.3	(94.5-112.6)
<u>Lung and Bronchus</u>									
Male	59	67.8	87.0	(66.2-112.3)					
Female	76	70.2	108.3	(85.3-135.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wayland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	16.1	80.7	(42.9-137.9)	Male	11	10.7	103.0	(51.3-184.3)
Female	5	5.3	94.3	(30.4-220.0)	Female	15	7.8	192.2	(107.5-317.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.1	nc	(nc-nc)	Male	4	2.7	nc	(nc-nc)
Female	7	2.4	288.9	(115.7-595.2)	Female	0	1.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	16	9.2	173.2	(98.9-281.3)
Female	86	60.4	142.3	(113.8-175.8)	Female	10	7.0	143.4	(68.6-263.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.2	nc	(nc-nc)	Male	6	6.8	88.2	(32.2-192.0)
<u>Colon / Rectum</u>					Female	0	2.9	nc	(nc-nc)
Male	22	19.7	111.9	(70.1-169.5)	<u>Ovary</u>				
Female	18	17.1	105.4	(62.4-166.6)	Female	6	5.6	107.0	(39.1-232.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	4.4	nc	(nc-nc)	Male	7	5.3	132.3	(53.0-272.7)
Female	0	1.1	nc	(nc-nc)	Female	4	4.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	1.1	nc	(nc-nc)	Male	63	64.9	97.1	(74.6-124.2)
Female	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	3.8	nc	(nc-nc)
Male	5	9.0	55.3	(17.8-129.1)	Female	0	1.9	nc	(nc-nc)
Female	4	4.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.6	nc	(nc-nc)
Male	3	2.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	5	3.4	147.0	(47.4-343.0)
<u>Leukemia</u>					Female	16	10.2	157.5	(90.0-255.8)
Male	4	5.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	3.9	153.9	(56.2-334.9)	Female	10	13.9	71.8	(34.4-132.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	4.9	nc	(nc-nc)	Male	208	222.1	93.6	(81.3-107.3)
Female	3	1.5	nc	(nc-nc)	Female	230	200.5	114.7	(100.3-130.5)
<u>Lung and Bronchus</u>									
Male	23	30.3	75.9	(48.1-113.8)					
Female	26	29.2	89.2	(58.2-130.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Webster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	29	19.1	151.6	(101.5-217.8)	Male	7	12.5	55.9	(22.4-115.1)
Female	10	8.0	125.3	(60.0-230.4)	Female	2	10.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	3.6	194.7	(78.0-401.1)	Male	2	3.2	nc	(nc-nc)
Female	3	3.4	nc	(nc-nc)	Female	2	2.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	11	10.9	101.1	(50.4-180.9)
Female	74	76.6	96.6	(75.8-121.2)	Female	12	10.0	119.7	(61.8-209.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	2.9	208.6	(76.2-454.2)	Male	5	7.7	65.3	(21.1-152.4)
<u>Colon / Rectum</u>					Female	4	3.9	nc	(nc-nc)
Male	32	22.9	139.8	(95.6-197.3)	<u>Ovary</u>				
Female	34	26.8	126.8	(87.8-177.3)	Female	6	7.5	80.2	(29.3-174.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	5.1	117.8	(43.0-256.4)	Male	9	6.2	146.0	(66.6-277.2)
Female	1	1.6	nc	(nc-nc)	Female	5	7.6	65.4	(21.1-152.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	1.6	nc	(nc-nc)	Male	59	74.6	79.0	(60.2-102.0)
Female	0	1.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	4.4	113.1	(36.5-264.0)
Male	10	10.3	97.3	(46.6-178.9)	Female	0	3.1	nc	(nc-nc)
Female	7	6.5	108.1	(43.3-222.8)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.6	nc	(nc-nc)
Male	3	3.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	0.9	nc	(nc-nc)	Male	2	4.0	nc	(nc-nc)
<u>Leukemia</u>					Female	9	13.0	69.3	(31.6-131.7)
Male	13	6.9	188.3	(100.2-322.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	11	5.9	187.2	(93.3-335.0)	Female	18	17.2	104.7	(62.0-165.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	5.5	nc	(nc-nc)	Male	271	259.2	104.5	(92.5-117.8)
Female	7	2.1	329.8	(132.1-679.5)	Female	274	273.7	100.1	(88.6-112.7)
<u>Lung and Bronchus</u>									
Male	39	35.3	110.5	(78.6-151.1)					
Female	38	39.1	97.2	(68.8-133.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wellesley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	23	26.5	86.6	(54.9-130.0)	Male	26	17.1	152.3	(99.5-223.2)
Female	13	10.7	122.0	(64.9-208.7)	Female	23	14.8	155.9	(98.8-234.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	5.0	nc	(nc-nc)	Male	5	4.4	114.3	(36.8-266.7)
Female	2	4.9	nc	(nc-nc)	Female	4	3.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.8	nc	(nc-nc)	Male	21	15.0	140.1	(86.7-214.2)
Female	118	104.9	112.5	(93.1-134.8)	Female	19	13.8	138.2	(83.1-215.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	3.8	nc	(nc-nc)	Male	8	10.6	75.8	(32.6-149.3)
<u>Colon / Rectum</u>					Female	5	5.4	93.4	(30.1-217.9)
Male	18	31.8	56.6	(33.5-89.4)	<u>Ovary</u>				
Female	25	35.5	70.5	(45.6-104.1)	Female	11	10.4	106.0	(52.8-189.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	7.0	nc	(nc-nc)	Male	14	8.6	163.0	(89.0-273.5)
Female	2	2.2	nc	(nc-nc)	Female	4	10.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.1	nc	(nc-nc)	Male	125	102.2	122.3	(101.8-145.7)
Female	4	2.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	6.1	81.6	(26.3-190.4)
Male	11	14.2	77.6	(38.7-138.9)	Female	5	4.1	121.7	(39.2-284.0)
Female	10	8.8	113.4	(54.3-208.6)	<u>Testis</u>				
<u>Larynx</u>					Male	4	2.9	nc	(nc-nc)
Male	1	4.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.3	nc	(nc-nc)	Male	10	5.4	186.4	(89.2-342.8)
<u>Leukemia</u>					Female	26	18.2	142.8	(93.2-209.2)
Male	11	9.8	112.2	(55.9-200.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	9	8.1	110.8	(50.5-210.3)	Female	24	23.9	100.5	(64.4-149.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	11	7.6	144.0	(71.8-257.7)	Male	357	356.9	100.0	(89.9-110.9)
Female	2	2.9	nc	(nc-nc)	Female	366	373.4	98.0	(88.2-108.6)
<u>Lung and Bronchus</u>									
Male	20	48.9	40.9	(25.0-63.2)					
Female	29	53.1	54.6	(36.5-78.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wellfleet

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	5.6	196.2	(97.8-351.1)	Male	2	3.3	nc	(nc-nc)
Female	1	2.0	nc	(nc-nc)	Female	5	2.6	189.0	(60.9-441.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.8	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.2	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	22	21.2	104.0	(65.1-157.4)	Female	2	2.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.7	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.0	nc	(nc-nc)
Male	9	6.3	143.5	(65.5-272.5)	<u>Ovary</u>				
Female	3	6.0	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.4	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	24	21.4	112.0	(71.7-166.6)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.2	nc	(nc-nc)
Male	1	2.8	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	0	1.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Leukemia</u>					Female	0	3.2	nc	(nc-nc)
Male	0	1.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	1.3	nc	(nc-nc)	Female	3	5.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	1.5	nc	(nc-nc)	Male	67	71.6	93.5	(72.5-118.8)
Female	1	0.5	nc	(nc-nc)	Female	59	71.7	82.3	(62.6-106.1)
<u>Lung and Bronchus</u>									
Male	5	10.5	47.6	(15.4-111.2)					
Female	8	11.2	71.3	(30.7-140.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wendell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.1	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	4	4.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	2	1.4	nc	(nc-nc)	<u>Ovary</u>				
Female	2	0.9	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	6	5.4	110.9	(40.5-241.3)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.3	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	1	0.9	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.4	nc	(nc-nc)	Male	16	16.6	96.3	(55.0-156.4)
Female	1	0.1	nc	(nc-nc)	Female	12	13.2	91.2	(47.1-159.3)
<u>Lung and Bronchus</u>									
Male	2	2.2	nc	(nc-nc)					
Female	3	1.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wenham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	4.8	nc	(nc-nc)	Male	5	3.0	165.7	(53.4-386.7)
Female	5	1.3	384.5	(123.9-897.4)	Female	7	2.1	337.0	(135.0-694.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.9	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	17	14.0	121.4	(70.7-194.3)	Female	0	1.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.6	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.7	nc	(nc-nc)
Male	4	5.8	nc	(nc-nc)	<u>Ovary</u>				
Female	6	4.5	133.7	(48.8-291.0)	Female	2	1.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.2	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	18	16.3	110.3	(65.3-174.3)
Female	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.1	nc	(nc-nc)
Male	2	2.4	nc	(nc-nc)	Female	2	0.5	nc	(nc-nc)
Female	5	1.1	441.9	(142.4-1031.2)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.6	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.2	nc	(nc-nc)	Male	4	0.9	nc	(nc-nc)
<u>Leukemia</u>					Female	3	2.8	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	1.1	nc	(nc-nc)	Female	7	3.0	233.0	(93.4-480.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	1.3	nc	(nc-nc)	Male	60	61.7	97.3	(74.2-125.2)
Female	0	0.4	nc	(nc-nc)	Female	74	48.7	152.0	(119.3-190.8)
<u>Lung and Bronchus</u>									
Male	7	8.5	81.9	(32.8-168.8)					
Female	5	6.4	77.8	(25.1-181.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Boylston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	8.9	78.7	(31.5-162.1)	Male	5	6.6	76.0	(24.5-177.3)
Female	3	2.8	nc	(nc-nc)	Female	5	3.8	131.0	(42.2-305.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.9	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	9	5.7	158.8	(72.5-301.5)
Female	39	28.5	137.1	(97.4-187.4)	Female	1	3.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.0	nc	(nc-nc)	Male	0	4.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.4	nc	(nc-nc)
Male	5	11.4	43.7	(14.1-102.1)	<u>Ovary</u>				
Female	6	9.3	64.2	(23.5-139.8)	Female	2	2.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.5	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	2.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.1	nc	(nc-nc)	Male	22	36.0	61.0	(38.2-92.4)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.2	nc	(nc-nc)
Male	4	5.4	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
Female	1	2.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	2.0	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	5	2.5	199.8	(64.4-466.3)
<u>Leukemia</u>					Female	3	4.6	nc	(nc-nc)
Male	1	3.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	2.0	nc	(nc-nc)	Female	9	6.6	135.3	(61.8-256.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	2.8	nc	(nc-nc)	Male	89	128.7	69.1	(55.5-85.1)
Female	2	0.8	nc	(nc-nc)	Female	102	99.5	102.6	(83.6-124.5)
<u>Lung and Bronchus</u>									
Male	11	16.4	67.1	(33.5-120.1)					
Female	18	14.4	124.6	(73.8-196.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	8.5	94.3	(40.6-185.7)	Male	8	5.6	143.7	(61.9-283.2)
Female	5	3.3	151.9	(49.0-354.5)	Female	2	4.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.6	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	3	4.8	nc	(nc-nc)
Female	22	30.7	71.6	(44.9-108.5)	Female	4	4.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.1	nc	(nc-nc)	Male	1	3.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.6	nc	(nc-nc)
Male	4	10.1	nc	(nc-nc)	<u>Ovary</u>				
Female	11	11.1	99.1	(49.4-177.4)	Female	2	3.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	2.3	217.5	(70.1-507.5)	Male	2	2.8	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	2	3.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.6	nc	(nc-nc)	Male	43	34.2	125.6	(90.9-169.2)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	2.0	nc	(nc-nc)
Male	6	4.7	128.7	(47.0-280.2)	Female	0	1.3	nc	(nc-nc)
Female	1	2.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.0	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.4	nc	(nc-nc)	Male	7	1.8	389.7	(156.1-803.1)
<u>Leukemia</u>					Female	2	4.9	nc	(nc-nc)
Male	1	3.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	2.4	nc	(nc-nc)	Female	10	6.9	144.0	(68.9-264.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.5	nc	(nc-nc)	Male	121	116.1	104.2	(86.5-124.6)
Female	0	0.8	nc	(nc-nc)	Female	92	110.2	83.5	(67.3-102.4)
<u>Lung and Bronchus</u>									
Male	16	15.9	100.8	(57.6-163.7)					
Female	18	15.7	114.4	(67.8-180.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	4.9	123.7	(45.2-269.3)	Male	1	3.2	nc	(nc-nc)
Female	1	2.3	nc	(nc-nc)	Female	1	2.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.9	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	3	0.9	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	16	20.7	77.3	(44.1-125.5)	Female	0	2.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.1	nc	(nc-nc)
Male	6	6.0	100.2	(36.6-218.2)	<u>Ovary</u>				
Female	10	8.1	123.1	(58.9-226.3)	Female	3	2.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.3	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	14	20.0	70.1	(38.3-117.6)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.1	nc	(nc-nc)
Male	3	2.7	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.5	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<u>Leukemia</u>					Female	3	3.1	nc	(nc-nc)
Male	1	1.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.7	nc	(nc-nc)	Female	1	4.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.5	nc	(nc-nc)	Male	54	67.4	80.1	(60.2-104.6)
Female	0	0.6	nc	(nc-nc)	Female	60	75.7	79.3	(60.5-102.1)
<u>Lung and Bronchus</u>									
Male	13	9.0	144.2	(76.7-246.7)					
Female	14	10.6	131.6	(71.9-220.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Newbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	4.6	nc	(nc-nc)	Male	6	3.2	185.6	(67.8-404.1)
Female	1	1.2	nc	(nc-nc)	Female	7	2.2	319.4	(128.0-658.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	0.9	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	2.8	nc	(nc-nc)
Female	13	16.4	79.2	(42.1-135.5)	Female	1	1.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.7	nc	(nc-nc)	Male	4	2.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.8	nc	(nc-nc)
Male	4	5.8	nc	(nc-nc)	<u>Ovary</u>				
Female	4	4.3	nc	(nc-nc)	Female	3	1.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.4	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.4	nc	(nc-nc)	Male	20	20.7	96.6	(59.0-149.2)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.1	nc	(nc-nc)
Male	1	2.8	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.6	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
<u>Leukemia</u>					Female	4	3.2	nc	(nc-nc)
Male	1	1.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.0	nc	(nc-nc)	Female	4	3.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.5	nc	(nc-nc)	Male	59	67.5	87.4	(66.5-112.7)
Female	0	0.4	nc	(nc-nc)	Female	52	52.1	99.8	(74.5-130.9)
<u>Lung and Bronchus</u>									
Male	7	8.8	79.5	(31.9-163.9)					
Female	5	6.4	78.5	(25.3-183.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Springfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	29	32.3	89.8	(60.1-128.9)	Male	18	21.1	85.2	(50.4-134.6)
Female	11	12.7	86.7	(43.2-155.1)	Female	14	17.2	81.5	(44.5-136.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	6.1	97.8	(35.7-212.8)	Male	4	5.4	nc	(nc-nc)
Female	4	5.4	nc	(nc-nc)	Female	3	4.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.9	nc	(nc-nc)	Male	18	18.3	98.3	(58.2-155.4)
Female	128	122.8	104.3	(87.0-124.0)	Female	15	16.1	93.4	(52.2-154.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	7	4.6	150.9	(60.5-311.0)	Male	22	12.8	171.3	(107.3-259.4)
<u>Colon / Rectum</u>					Female	7	6.2	113.0	(45.3-232.8)
Male	42	38.6	108.9	(78.5-147.2)	<u>Ovary</u>				
Female	33	42.3	78.0	(53.7-109.6)	Female	10	11.9	84.1	(40.3-154.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	13	8.6	151.5	(80.6-259.1)	Male	8	10.5	76.4	(32.9-150.6)
Female	3	2.6	nc	(nc-nc)	Female	10	12.1	82.4	(39.5-151.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.7	nc	(nc-nc)	Male	121	125.2	96.7	(80.2-115.5)
Female	1	2.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	9	7.4	121.2	(55.3-230.0)
Male	18	17.5	103.0	(61.0-162.7)	Female	7	4.9	143.3	(57.4-295.3)
Female	10	10.5	95.4	(45.6-175.4)	<u>Testis</u>				
<u>Larynx</u>					Male	1	4.2	nc	(nc-nc)
Male	4	5.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.4	nc	(nc-nc)	Male	3	6.8	nc	(nc-nc)
<u>Leukemia</u>					Female	12	21.2	56.7	(29.3-99.0)
Male	11	11.7	94.1	(46.9-168.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	9.3	86.2	(37.1-169.8)	Female	29	27.4	105.7	(70.8-151.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	9.5	74.0	(29.6-152.4)	Male	426	437.4	97.4	(88.4-107.1)
Female	2	3.4	nc	(nc-nc)	Female	419	438.5	95.6	(86.6-105.2)
<u>Lung and Bronchus</u>									
Male	60	60.5	99.1	(75.6-127.6)					
Female	73	63.7	114.6	(89.9-144.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Stockbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.5	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	3	1.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	15	8.5	177.4	(99.2-292.5)	Female	2	1.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	3	2.9	nc	(nc-nc)	<u>Ovary</u>				
Female	3	2.9	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.1	nc	(nc-nc)	Male	12	9.2	130.2	(67.2-227.5)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.6	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.2	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.6	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.7	nc	(nc-nc)	Male	26	31.6	82.2	(53.7-120.4)
Female	0	0.2	nc	(nc-nc)	Female	31	30.1	102.9	(69.9-146.0)
<u>Lung and Bronchus</u>									
Male	2	4.4	nc	(nc-nc)					
Female	5	4.6	109.3	(35.2-255.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Tisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	2.5	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	4	1.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.5	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	11	12.2	90.0	(44.9-161.0)	Female	2	1.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.6	nc	(nc-nc)
Male	2	3.3	nc	(nc-nc)	<u>Ovary</u>				
Female	2	3.4	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.8	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	18	11.6	155.5	(92.1-245.7)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	0.6	nc	(nc-nc)
Male	2	1.6	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.3	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	4	2.0	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.8	nc	(nc-nc)	Female	0	2.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.9	nc	(nc-nc)	Male	49	37.6	130.4	(96.4-172.4)
Female	0	0.3	nc	(nc-nc)	Female	37	40.6	91.1	(64.2-125.6)
<u>Lung and Bronchus</u>									
Male	2	4.8	nc	(nc-nc)					
Female	4	6.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	20.5	92.6	(55.7-144.6)	Male	8	13.4	59.8	(25.8-117.9)
Female	9	6.8	133.3	(60.8-253.1)	Female	9	9.8	91.6	(41.8-173.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	4.0	nc	(nc-nc)	Male	2	3.4	nc	(nc-nc)
Female	3	3.0	nc	(nc-nc)	Female	4	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	12	11.9	101.1	(52.2-176.6)
Female	68	69.1	98.4	(76.4-124.8)	Female	7	8.7	80.6	(32.3-166.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.8	nc	(nc-nc)	Male	3	8.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	3.4	nc	(nc-nc)
Male	21	25.1	83.5	(51.7-127.7)	<u>Ovary</u>				
Female	27	23.2	116.2	(76.6-169.1)	Female	7	6.6	105.8	(42.4-217.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	5.1	97.3	(31.4-227.1)	Male	5	6.6	75.9	(24.5-177.2)
Female	1	1.4	nc	(nc-nc)	Female	3	6.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.7	nc	(nc-nc)	Male	56	71.6	78.2	(59.0-101.5)
Female	1	1.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	4.8	nc	(nc-nc)
Male	17	10.8	158.0	(92.0-253.0)	Female	1	2.7	nc	(nc-nc)
Female	4	5.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.8	nc	(nc-nc)
Male	2	3.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.8	nc	(nc-nc)	Male	8	4.4	182.8	(78.7-360.2)
<u>Leukemia</u>					Female	12	12.7	94.1	(48.6-164.4)
Male	6	7.7	77.9	(28.5-169.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	5.2	nc	(nc-nc)	Female	12	14.9	80.6	(41.6-140.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	5.8	nc	(nc-nc)	Male	215	269.2	79.9	(69.5-91.3)
Female	2	1.8	nc	(nc-nc)	Female	226	241.6	93.5	(81.7-106.6)
<u>Lung and Bronchus</u>									
Male	20	36.7	54.5	(33.3-84.1)					
Female	35	32.9	106.3	(74.0-147.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	37	43.4	85.2	(60.0-117.4)	Male	26	28.3	92.0	(60.1-134.9)
Female	10	16.6	60.4	(28.9-111.0)	Female	11	22.9	48.1	(24.0-86.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	8.4	83.7	(33.5-172.5)	Male	9	7.1	127.3	(58.1-241.6)
Female	7	7.2	96.9	(38.8-199.7)	Female	6	5.9	101.6	(37.1-221.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.3	nc	(nc-nc)	Male	16	24.9	64.4	(36.8-104.5)
Female	165	160.4	102.9	(87.8-119.9)	Female	21	21.0	99.9	(61.8-152.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	10	6.1	164.3	(78.6-302.1)	Male	9	17.0	52.8	(24.1-100.3)
<u>Colon / Rectum</u>					Female	11	8.1	135.3	(67.4-242.0)
Male	48	52.6	91.2	(67.2-120.9)	<u>Ovary</u>				
Female	51	55.4	92.1	(68.6-121.1)	Female	18	15.8	113.8	(67.4-179.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	18	11.1	162.8	(96.4-257.3)	Male	9	13.9	64.5	(29.4-122.5)
Female	3	3.4	nc	(nc-nc)	Female	13	15.9	82.0	(43.6-140.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	6	3.9	153.2	(55.9-333.5)	Male	151	156.9	96.2	(81.5-112.9)
Female	6	3.3	183.1	(66.9-398.6)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	13	10.0	129.5	(68.9-221.5)
Male	18	22.9	78.7	(46.6-124.4)	Female	5	6.4	77.7	(25.0-181.3)
Female	15	13.7	109.6	(61.3-180.8)	<u>Testis</u>				
<u>Larynx</u>					Male	8	6.4	125.4	(54.0-247.1)
Male	3	6.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.9	nc	(nc-nc)	Male	5	9.2	54.4	(17.5-127.0)
<u>Leukemia</u>					Female	19	28.3	67.1	(40.4-104.8)
Male	11	16.2	67.7	(33.8-121.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	11	12.3	89.1	(44.4-159.5)	Female	40	36.0	111.0	(79.3-151.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	12.3	57.1	(22.9-117.6)	Male	528	575.2	91.8	(84.1-100.0)
Female	4	4.4	nc	(nc-nc)	Female	546	574.9	95.0	(87.2-103.3)
<u>Lung and Bronchus</u>									
Male	85	78.0	108.9	(87.0-134.7)					
Female	74	82.5	89.7	(70.4-112.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	19.4	87.7	(51.1-140.4)	Male	22	14.2	155.0	(97.1-234.7)
Female	2	6.4	nc	(nc-nc)	Female	16	10.8	147.8	(84.4-240.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	4.4	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
Female	3	3.4	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.6	nc	(nc-nc)	Male	12	12.3	97.5	(50.3-170.4)
Female	79	79.3	99.7	(78.9-124.2)	Female	9	8.7	102.9	(47.0-195.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.3	nc	(nc-nc)	Male	12	9.4	127.7	(65.9-223.0)
<u>Colon / Rectum</u>					Female	2	3.7	nc	(nc-nc)
Male	23	25.4	90.6	(57.4-135.9)	<u>Ovary</u>				
Female	13	21.8	59.6	(31.7-101.9)	Female	9	7.3	122.9	(56.1-233.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	5.7	nc	(nc-nc)	Male	2	6.5	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	5	6.0	83.7	(27.0-195.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.9	nc	(nc-nc)	Male	85	85.1	99.8	(79.7-123.5)
Female	2	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	4.8	125.6	(45.9-273.4)
Male	10	12.1	82.6	(39.5-151.8)	Female	4	2.5	nc	(nc-nc)
Female	3	6.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	3.1	nc	(nc-nc)
Male	4	3.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.9	nc	(nc-nc)	Male	4	5.1	nc	(nc-nc)
<u>Leukemia</u>					Female	17	15.5	109.6	(63.8-175.5)
Male	11	7.8	141.2	(70.4-252.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	5.3	95.2	(30.7-222.1)	Female	22	17.7	124.5	(78.0-188.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	6.6	nc	(nc-nc)	Male	277	289.1	95.8	(84.9-107.8)
Female	1	1.8	nc	(nc-nc)	Female	231	257.7	89.6	(78.5-102.0)
<u>Lung and Bronchus</u>									
Male	26	37.1	70.0	(45.7-102.6)					
Female	23	32.9	69.9	(44.3-104.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westhampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.0	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.1	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	6	7.7	78.1	(28.5-170.0)	Female	0	0.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	0	2.5	nc	(nc-nc)	<u>Ovary</u>				
Female	1	2.0	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.6	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.2	nc	(nc-nc)	Male	12	8.2	146.4	(75.6-255.8)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.5	nc	(nc-nc)
Male	2	1.2	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.5	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	0.5	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.7	nc	(nc-nc)	Male	25	28.3	88.4	(57.2-130.5)
Female	0	0.2	nc	(nc-nc)	Female	14	25.0	55.9	(30.6-93.9)
<u>Lung and Bronchus</u>									
Male	4	3.8	nc	(nc-nc)					
Female	0	3.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westminster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	7.3	136.9	(65.5-251.7)	Male	5	5.1	97.7	(31.5-227.9)
Female	2	2.4	nc	(nc-nc)	Female	11	4.0	275.0	(137.1-492.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.5	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	7	4.5	156.6	(62.7-322.6)
Female	27	30.4	88.8	(58.5-129.2)	Female	4	3.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.2	nc	(nc-nc)	Male	0	3.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	6	1.4	419.1	(153.1-912.3)
Male	13	9.1	143.0	(76.1-244.6)	<u>Ovary</u>				
Female	1	7.7	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.1	nc	(nc-nc)	Male	5	2.4	206.4	(66.5-481.6)
Female	2	0.5	nc	(nc-nc)	Female	4	2.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.7	nc	(nc-nc)	Male	22	30.0	73.2	(45.9-110.9)
Female	2	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.7	nc	(nc-nc)
Male	3	4.3	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	4	2.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.1	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
<u>Leukemia</u>					Female	4	5.8	nc	(nc-nc)
Male	2	2.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.8	nc	(nc-nc)	Female	7	7.3	95.3	(38.2-196.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.3	nc	(nc-nc)	Male	94	103.9	90.5	(73.1-110.7)
Female	0	0.7	nc	(nc-nc)	Female	96	97.5	98.5	(79.8-120.3)
<u>Lung and Bronchus</u>									
Male	11	13.7	80.1	(39.9-143.3)					
Female	11	12.8	85.8	(42.8-153.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Weston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	18.9	58.1	(29.0-104.0)	Male	15	11.2	133.4	(74.6-220.1)
Female	9	5.6	161.4	(73.6-306.4)	Female	6	7.1	84.8	(31.0-184.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.0	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
Female	3	2.3	nc	(nc-nc)	Female	0	2.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.6	nc	(nc-nc)	Male	4	9.7	nc	(nc-nc)
Female	56	53.2	105.2	(79.5-136.6)	Female	8	7.0	114.3	(49.2-225.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.8	nc	(nc-nc)	Male	2	6.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	5	2.7	184.5	(59.5-430.6)
Male	9	21.7	41.4	(18.9-78.6)	<u>Ovary</u>				
Female	18	18.1	99.2	(58.8-156.8)	Female	2	5.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	4.8	nc	(nc-nc)	Male	2	6.0	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	6	5.3	113.0	(41.3-246.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.0	nc	(nc-nc)	Male	69	70.9	97.3	(75.7-123.2)
Female	1	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	4.3	nc	(nc-nc)
Male	5	9.2	54.2	(17.5-126.5)	Female	3	2.1	nc	(nc-nc)
Female	3	4.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.1	nc	(nc-nc)
Male	3	2.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	1	3.1	nc	(nc-nc)
<u>Leukemia</u>					Female	10	8.3	120.8	(57.9-222.3)
Male	5	6.4	78.1	(25.2-182.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	4.0	176.2	(70.6-363.1)	Female	7	12.3	56.8	(22.8-117.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	4.9	nc	(nc-nc)	Male	178	242.2	73.5	(63.1-85.1)
Female	1	1.5	nc	(nc-nc)	Female	186	189.4	98.2	(84.6-113.4)
<u>Lung and Bronchus</u>									
Male	23	34.6	66.5	(42.1-99.7)					
Female	25	28.3	88.4	(57.2-130.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	29	21.8	133.1	(89.1-191.2)	Male	8	13.6	58.8	(25.3-115.9)
Female	14	7.8	180.6	(98.6-303.0)	Female	13	10.3	125.9	(67.0-215.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.7	nc	(nc-nc)	Male	6	3.5	169.2	(61.8-368.2)
Female	1	3.2	nc	(nc-nc)	Female	3	2.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	11	11.8	93.6	(46.7-167.5)
Female	66	77.0	85.7	(66.3-109.1)	Female	9	9.9	91.2	(41.6-173.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	2.7	224.2	(81.9-487.9)	Male	8	8.2	97.7	(42.1-192.6)
<u>Colon / Rectum</u>					Female	6	3.9	155.0	(56.6-337.4)
Male	26	25.3	102.7	(67.0-150.4)	<u>Ovary</u>				
Female	29	24.9	116.2	(77.8-167.0)	Female	5	7.4	67.3	(21.7-157.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	5.7	105.8	(38.6-230.2)	Male	9	7.0	128.4	(58.6-243.8)
Female	2	1.6	nc	(nc-nc)	Female	9	7.3	123.1	(56.1-233.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.5	nc	(nc-nc)	Male	99	83.5	118.5	(96.3-144.3)
Female	1	1.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	7	5.0	141.2	(56.6-290.9)
Male	11	11.2	98.5	(49.1-176.3)	Female	3	2.8	nc	(nc-nc)
Female	6	6.6	91.4	(33.4-198.9)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.1	nc	(nc-nc)
Male	6	3.3	182.7	(66.7-397.6)	<u>Thyroid</u>				
Female	2	0.9	nc	(nc-nc)	Male	8	4.1	196.0	(84.4-386.2)
<u>Leukemia</u>					Female	14	12.4	113.1	(61.8-189.7)
Male	8	7.5	107.1	(46.1-211.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	5.4	nc	(nc-nc)	Female	21	18.2	115.3	(71.3-176.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	6.0	nc	(nc-nc)	Male	301	286.7	105.0	(93.5-117.6)
Female	2	2.1	nc	(nc-nc)	Female	260	270.3	96.2	(84.9-108.6)
<u>Lung and Bronchus</u>									
Male	26	40.1	64.8	(42.3-94.9)					
Female	27	40.6	66.5	(43.8-96.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westwood

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	20.6	77.5	(44.3-125.9)	Male	21	12.1	173.4	(107.3-265.1)
Female	2	7.8	nc	(nc-nc)	Female	18	9.2	194.6	(115.3-307.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	3.3	149.4	(48.2-348.7)	Male	1	3.2	nc	(nc-nc)
Female	1	3.0	nc	(nc-nc)	Female	5	2.8	178.4	(57.5-416.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	12	10.9	110.0	(56.8-192.2)
Female	82	68.9	118.9	(94.6-147.6)	Female	10	9.6	104.2	(49.9-191.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.3	nc	(nc-nc)	Male	6	7.0	85.5	(31.2-186.1)
<u>Colon / Rectum</u>					Female	5	3.6	139.6	(45.0-325.9)
Male	18	24.2	74.4	(44.1-117.7)	<u>Ovary</u>				
Female	30	26.9	111.4	(75.2-159.1)	Female	5	6.8	73.4	(23.7-171.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	4.8	104.6	(33.7-244.1)	Male	7	6.4	109.0	(43.7-224.5)
Female	2	1.6	nc	(nc-nc)	Female	11	7.6	144.1	(71.8-257.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.2	nc	(nc-nc)	Male	66	64.9	101.7	(78.6-129.4)
Female	1	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	4.7	nc	(nc-nc)
Male	7	9.6	72.6	(29.1-149.7)	Female	3	3.2	nc	(nc-nc)
Female	2	5.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.6	nc	(nc-nc)
Male	1	2.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.8	nc	(nc-nc)	Male	8	3.3	239.1	(103.0-471.2)
<u>Leukemia</u>					Female	12	10.1	118.8	(61.3-207.6)
Male	7	7.3	95.7	(38.3-197.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	5.6	88.8	(28.6-207.3)	Female	8	15.1	53.0	(22.8-104.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	5.2	nc	(nc-nc)	Male	246	250.1	98.4	(86.5-111.5)
Female	2	2.1	nc	(nc-nc)	Female	277	253.1	109.4	(96.9-123.1)
<u>Lung and Bronchus</u>									
Male	27	35.3	76.5	(50.4-111.3)					
Female	47	36.9	127.5	(93.7-169.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Weymouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	54	62.5	86.4	(64.9-112.7)	Male	36	40.4	89.0	(62.4-123.3)
Female	24	24.3	98.6	(63.2-146.8)	Female	38	33.8	112.5	(79.6-154.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	15	11.6	129.3	(72.3-213.3)	Male	11	10.3	106.4	(53.0-190.4)
Female	13	10.4	125.5	(66.8-214.6)	Female	9	8.8	101.8	(46.4-193.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.8	nc	(nc-nc)	Male	43	35.3	121.7	(88.1-163.9)
Female	239	244.0	98.0	(85.9-111.2)	Female	33	31.2	105.8	(72.8-148.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	13	9.2	140.9	(74.9-240.9)	Male	33	24.4	135.4	(93.2-190.2)
<u>Colon / Rectum</u>					Female	12	12.2	98.4	(50.8-171.9)
Male	75	75.2	99.7	(78.4-125.0)	<u>Ovary</u>				
Female	91	80.8	112.6	(90.7-138.3)	Female	32	23.4	136.8	(93.6-193.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	26	16.2	160.6	(104.9-235.3)	Male	23	20.0	114.8	(72.8-172.3)
Female	1	5.1	nc	(nc-nc)	Female	24	23.2	103.4	(66.2-153.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	9	5.0	178.4	(81.4-338.7)	Male	199	233.3	85.3	(73.9-98.0)
Female	3	4.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	10	14.4	69.3	(33.2-127.5)
Male	36	32.9	109.3	(76.5-151.3)	Female	7	9.2	75.8	(30.4-156.3)
Female	25	20.6	121.3	(78.5-179.1)	<u>Testis</u>				
<u>Larynx</u>					Male	7	8.1	85.9	(34.4-177.0)
Male	7	9.4	74.4	(29.8-153.2)	<u>Thyroid</u>				
Female	3	2.9	nc	(nc-nc)	Male	15	12.8	116.9	(65.4-192.7)
<u>Leukemia</u>					Female	48	42.3	113.5	(83.7-150.5)
Male	20	22.6	88.6	(54.1-136.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	14	17.7	79.1	(43.2-132.8)	Female	47	55.0	85.4	(62.7-113.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	14	17.9	78.3	(42.8-131.3)	Male	828	832.1	99.5	(92.8-106.5)
Female	4	6.6	nc	(nc-nc)	Female	889	857.9	103.6	(96.9-110.7)
<u>Lung and Bronchus</u>									
Male	128	114.2	112.1	(93.5-133.3)					
Female	149	124.3	119.8	(101.4-140.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Whately

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.8	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	3	0.5	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	9	6.6	135.8	(61.9-257.7)	Female	0	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.3	nc	(nc-nc)
Male	1	2.4	nc	(nc-nc)	<u>Ovary</u>				
Female	4	1.6	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	5	7.7	65.3	(21.0-152.3)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	2	1.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.2	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.4	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.6	nc	(nc-nc)	Male	18	26.7	67.5	(40.0-106.7)
Female	0	0.1	nc	(nc-nc)	Female	20	20.6	97.2	(59.3-150.1)
<u>Lung and Bronchus</u>									
Male	4	3.4	nc	(nc-nc)					
Female	0	2.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Whitman

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	12.7	117.8	(65.9-194.2)	Male	8	9.0	89.1	(38.4-175.6)
Female	1	4.7	nc	(nc-nc)	Female	10	7.6	131.2	(62.8-241.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.7	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	4	7.8	nc	(nc-nc)
Female	46	53.8	85.5	(62.6-114.1)	Female	9	6.3	142.4	(65.0-270.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.2	nc	(nc-nc)	Male	5	5.7	87.0	(28.0-203.0)
<u>Colon / Rectum</u>					Female	4	2.6	nc	(nc-nc)
Male	18	16.3	110.3	(65.3-174.3)	<u>Ovary</u>				
Female	25	15.7	159.7	(103.3-235.7)	Female	4	5.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	3.5	169.9	(62.1-369.9)	Male	5	4.2	118.3	(38.1-276.1)
Female	3	1.0	nc	(nc-nc)	Female	4	4.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.3	nc	(nc-nc)	Male	37	51.5	71.8	(50.5-99.0)
Female	0	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.1	nc	(nc-nc)
Male	10	7.4	135.5	(64.8-249.1)	Female	2	1.7	nc	(nc-nc)
Female	1	4.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	2.2	nc	(nc-nc)
Male	5	2.1	241.8	(77.9-564.2)	<u>Thyroid</u>				
Female	1	0.6	nc	(nc-nc)	Male	1	3.2	nc	(nc-nc)
<u>Leukemia</u>					Female	11	10.4	105.5	(52.6-188.8)
Male	3	5.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	3.7	nc	(nc-nc)	Female	16	12.5	128.3	(73.3-208.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	4.1	nc	(nc-nc)	Male	169	181.6	93.0	(79.5-108.2)
Female	2	1.4	nc	(nc-nc)	Female	184	181.2	101.6	(87.4-117.3)
<u>Lung and Bronchus</u>									
Male	28	23.4	119.5	(79.4-172.8)					
Female	27	24.5	110.1	(72.6-160.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wilbraham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	18.7	96.5	(57.1-152.5)	Male	25	11.5	216.5	(140.1-319.6)
Female	11	7.0	156.4	(78.0-279.8)	Female	11	9.1	120.6	(60.1-215.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	3.2	157.5	(50.8-367.6)	Male	6	3.0	197.0	(72.0-428.9)
Female	1	2.9	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	16	10.2	156.8	(89.6-254.7)
Female	71	69.6	102.1	(79.7-128.7)	Female	13	8.9	146.2	(77.8-250.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.4	nc	(nc-nc)	Male	4	7.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	3.5	nc	(nc-nc)
Male	15	22.3	67.3	(37.6-110.9)	<u>Ovary</u>				
Female	27	22.9	117.7	(77.6-171.3)	Female	7	6.7	104.3	(41.8-214.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	4.7	nc	(nc-nc)	Male	10	6.0	167.9	(80.4-308.7)
Female	1	1.5	nc	(nc-nc)	Female	10	6.7	149.9	(71.8-275.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	1.2	nc	(nc-nc)	Male	88	66.9	131.5	(105.4-162.0)
Female	1	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	4.3	nc	(nc-nc)
Male	10	9.5	105.4	(50.5-193.9)	Female	3	2.6	nc	(nc-nc)
Female	9	5.9	152.3	(69.5-289.2)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.7	nc	(nc-nc)
Male	2	2.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.9	nc	(nc-nc)	Male	4	3.4	nc	(nc-nc)
<u>Leukemia</u>					Female	15	11.1	135.0	(75.5-222.7)
Male	7	6.6	106.8	(42.8-220.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	5.0	nc	(nc-nc)	Female	13	16.0	81.1	(43.1-138.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	5.2	nc	(nc-nc)	Male	257	241.0	106.6	(94.0-120.5)
Female	4	1.9	nc	(nc-nc)	Female	244	244.0	100.0	(87.8-113.4)
<u>Lung and Bronchus</u>									
Male	17	33.6	50.6	(29.5-81.0)					
Female	19	36.2	52.5	(31.6-82.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Williamsburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	3.3	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	3	0.4	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	1.9	nc	(nc-nc)
Female	13	11.0	117.9	(62.7-201.7)	Female	2	1.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.4	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.5	nc	(nc-nc)
Male	4	4.2	nc	(nc-nc)	<u>Ovary</u>				
Female	6	3.2	187.2	(68.3-407.4)	Female	3	1.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.9	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	12	12.6	95.2	(49.2-166.4)
Female	1	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.8	nc	(nc-nc)
Male	0	1.8	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Leukemia</u>					Female	0	2.0	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.7	nc	(nc-nc)	Female	5	2.6	195.7	(63.1-456.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.0	nc	(nc-nc)	Male	32	44.6	71.7	(49.0-101.2)
Female	0	0.3	nc	(nc-nc)	Female	48	36.4	131.9	(97.3-174.9)
<u>Lung and Bronchus</u>									
Male	2	5.9	nc	(nc-nc)					
Female	5	4.8	104.6	(33.7-244.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Williamstown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	12.0	49.9	(18.2-108.7)	Male	7	7.0	99.4	(39.8-204.9)
Female	1	5.0	nc	(nc-nc)	Female	5	5.5	91.7	(29.6-214.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.9	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	7	6.2	112.5	(45.1-231.9)
Female	27	40.6	66.4	(43.8-96.7)	Female	6	6.0	100.7	(36.8-219.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.3	nc	(nc-nc)	Male	1	4.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	2.2	nc	(nc-nc)
Male	7	13.6	51.6	(20.7-106.3)	<u>Ovary</u>				
Female	15	16.6	90.4	(50.5-149.0)	Female	3	4.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	2.9	nc	(nc-nc)	Male	0	3.7	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	Female	2	4.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.8	nc	(nc-nc)	Male	66	41.8	158.1	(122.3-201.1)
Female	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.7	nc	(nc-nc)
Male	3	5.6	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
Female	0	3.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.2	nc	(nc-nc)
Male	1	1.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
<u>Leukemia</u>					Female	3	5.7	nc	(nc-nc)
Male	3	4.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	3.4	nc	(nc-nc)	Female	5	9.2	54.4	(17.5-126.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	3.0	nc	(nc-nc)	Male	145	149.6	96.9	(81.8-114.0)
Female	1	1.2	nc	(nc-nc)	Female	111	154.6	71.8	(59.1-86.5)
<u>Lung and Bronchus</u>									
Male	18	21.5	83.6	(49.5-132.2)					
Female	29	23.7	122.3	(81.9-175.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wilmington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	29	21.9	132.1	(88.5-189.8)	Male	16	15.1	106.2	(60.7-172.5)
Female	10	7.8	128.0	(61.3-235.4)	Female	14	12.1	116.0	(63.4-194.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	4.5	nc	(nc-nc)	Male	2	3.7	nc	(nc-nc)
Female	5	3.7	133.9	(43.1-312.4)	Female	4	2.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	10	13.1	76.5	(36.6-140.7)
Female	97	87.8	110.4	(89.6-134.7)	Female	8	10.4	77.1	(33.2-151.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	3.5	nc	(nc-nc)	Male	8	9.4	84.7	(36.5-166.9)
<u>Colon / Rectum</u>					Female	7	4.2	166.0	(66.5-342.1)
Male	32	26.9	119.1	(81.5-168.1)	<u>Ovary</u>				
Female	21	25.7	81.8	(50.6-125.0)	Female	11	8.1	135.1	(67.3-241.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	6.0	nc	(nc-nc)	Male	6	7.2	83.5	(30.5-181.8)
Female	1	1.6	nc	(nc-nc)	Female	12	7.3	163.7	(84.5-286.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.0	nc	(nc-nc)	Male	90	87.9	102.3	(82.3-125.8)
Female	3	1.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	5.2	nc	(nc-nc)
Male	12	12.6	95.0	(49.0-165.9)	Female	3	2.9	nc	(nc-nc)
Female	9	7.1	126.9	(57.9-240.9)	<u>Testis</u>				
<u>Larynx</u>					Male	2	3.2	nc	(nc-nc)
Male	3	3.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.0	nc	(nc-nc)	Male	8	5.2	155.0	(66.8-305.5)
<u>Leukemia</u>					Female	10	16.5	60.6	(29.0-111.5)
Male	9	8.2	109.8	(50.1-208.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	6.0	99.8	(36.4-217.3)	Female	23	19.5	117.9	(74.7-177.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	6.7	nc	(nc-nc)	Male	321	306.7	104.7	(93.5-116.8)
Female	7	2.2	324.7	(130.1-669.0)	Female	325	295.6	109.9	(98.3-122.6)
<u>Lung and Bronchus</u>									
Male	50	41.3	121.2	(90.0-159.8)					
Female	55	41.2	133.5	(100.5-173.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Winchendon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	10.9	100.7	(50.2-180.3)	Male	2	7.6	nc	(nc-nc)
Female	1	2.5	nc	(nc-nc)	Female	1	4.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.3	nc	(nc-nc)	Male	5	1.9	264.2	(85.1-616.5)
Female	0	1.5	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	6.5	nc	(nc-nc)
Female	31	33.0	93.9	(63.8-133.3)	Female	4	3.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	1.4	nc	(nc-nc)	Male	2	4.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.5	nc	(nc-nc)
Male	15	13.6	110.0	(61.5-181.5)	<u>Ovary</u>				
Female	11	8.1	136.1	(67.8-243.5)	Female	4	3.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	3.1	nc	(nc-nc)	Male	4	3.6	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	4	2.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.0	nc	(nc-nc)	Male	42	46.0	91.3	(65.8-123.4)
Female	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.6	nc	(nc-nc)
Male	0	6.4	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	5	2.6	191.7	(61.8-447.4)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.5	nc	(nc-nc)
Male	1	1.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
<u>Leukemia</u>					Female	2	6.9	nc	(nc-nc)
Male	3	4.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.1	nc	(nc-nc)	Female	9	7.6	118.6	(54.1-225.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	3.5	nc	(nc-nc)	Male	137	156.2	87.7	(73.6-103.7)
Female	0	0.7	nc	(nc-nc)	Female	116	106.7	108.7	(89.8-130.3)
<u>Lung and Bronchus</u>									
Male	22	20.8	105.6	(66.2-159.9)					
Female	25	14.3	174.9	(113.2-258.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Winchester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	36	23.3	154.8	(108.4-214.3)	Male	25	15.2	164.5	(106.4-242.9)
Female	3	11.8	nc	(nc-nc)	Female	16	14.2	112.5	(64.2-182.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	4.4	159.3	(63.8-328.3)	Male	3	3.9	nc	(nc-nc)
Female	9	4.6	197.1	(89.9-374.1)	Female	4	4.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	20	13.2	151.7	(92.6-234.3)
Female	92	106.5	86.4	(69.6-105.9)	Female	9	14.4	62.5	(28.5-118.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	3.7	nc	(nc-nc)	Male	8	9.4	85.1	(36.6-167.6)
<u>Colon / Rectum</u>					Female	8	5.5	144.2	(62.1-284.2)
Male	22	28.3	77.6	(48.6-117.5)	<u>Ovary</u>				
Female	28	39.5	70.9	(47.1-102.4)	Female	9	10.5	85.5	(39.0-162.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	6.2	nc	(nc-nc)	Male	5	7.6	66.1	(21.3-154.2)
Female	3	2.4	nc	(nc-nc)	Female	5	11.4	43.9	(14.2-102.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.7	nc	(nc-nc)	Male	102	90.2	113.1	(92.2-137.3)
Female	1	1.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	5.4	nc	(nc-nc)
Male	19	12.6	150.6	(90.6-235.2)	Female	3	4.7	nc	(nc-nc)
Female	4	9.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	4	2.5	nc	(nc-nc)
Male	6	3.6	167.0	(61.0-363.5)	<u>Thyroid</u>				
Female	0	1.3	nc	(nc-nc)	Male	5	4.8	103.6	(33.4-241.7)
<u>Leukemia</u>					Female	23	16.3	141.5	(89.7-212.3)
Male	9	8.6	105.2	(48.0-199.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	8.5	82.4	(33.0-169.8)	Female	24	23.8	100.7	(64.5-149.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	6.8	73.7	(23.7-171.9)	Male	351	314.9	111.5	(100.1-123.8)
Female	0	3.0	nc	(nc-nc)	Female	313	387.0	80.9	(72.2-90.4)
<u>Lung and Bronchus</u>									
Male	45	43.0	104.8	(76.4-140.2)					
Female	34	56.6	60.1	(41.6-83.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Windsor

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.5	nc	(nc-nc)	Male	3	1.0	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.0	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	2	4.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	<u>Ovary</u>				
Female	0	1.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	6.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	2	0.8	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.3	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.5	nc	(nc-nc)	Male	13	21.4	60.7	(32.3-103.8)
Female	0	0.1	nc	(nc-nc)	Female	9	14.7	61.4	(28.0-116.6)
<u>Lung and Bronchus</u>									
Male	1	2.8	nc	(nc-nc)					
Female	0	1.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Winthrop

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	23	20.1	114.5	(72.5-171.8)	Male	21	13.2	159.4	(98.6-243.7)
Female	9	8.5	106.4	(48.5-201.9)	Female	21	11.9	177.2	(109.6-270.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.9	nc	(nc-nc)	Male	0	3.3	nc	(nc-nc)
Female	4	3.6	nc	(nc-nc)	Female	2	3.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	16	11.3	141.1	(80.6-229.1)
Female	98	84.9	115.4	(93.7-140.6)	Female	18	10.9	165.8	(98.2-262.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.3	nc	(nc-nc)	Male	9	7.8	115.0	(52.5-218.3)
<u>Colon / Rectum</u>					Female	4	4.2	nc	(nc-nc)
Male	24	24.0	100.1	(64.1-149.0)	<u>Ovary</u>				
Female	20	28.1	71.2	(43.5-110.0)	Female	12	8.1	147.4	(76.1-257.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	5.2	154.3	(66.5-304.1)	Male	7	6.5	108.1	(43.3-222.7)
Female	1	1.8	nc	(nc-nc)	Female	9	8.0	111.8	(51.0-212.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.7	nc	(nc-nc)	Male	71	74.5	95.3	(74.4-120.2)
Female	0	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	4.6	nc	(nc-nc)
Male	14	10.8	129.4	(70.7-217.1)	Female	2	3.2	nc	(nc-nc)
Female	13	7.1	182.5	(97.1-312.2)	<u>Testis</u>				
<u>Larynx</u>					Male	4	2.9	nc	(nc-nc)
Male	3	3.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.0	nc	(nc-nc)	Male	8	4.3	185.2	(79.8-365.0)
<u>Leukemia</u>					Female	11	15.0	73.4	(36.6-131.3)
Male	9	7.3	123.1	(56.2-233.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	6.2	80.0	(25.8-186.8)	Female	30	19.1	157.0	(105.9-224.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	5.7	87.7	(28.2-204.6)	Male	302	268.1	112.7	(100.3-126.1)
Female	2	2.3	nc	(nc-nc)	Female	340	298.5	113.9	(102.1-126.7)
<u>Lung and Bronchus</u>									
Male	45	37.0	121.6	(88.7-162.8)					
Female	50	42.9	116.6	(86.5-153.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Woburn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	45	42.6	105.6	(77.0-141.4)	Male	33	28.0	118.0	(81.2-165.7)
Female	15	16.6	90.1	(50.4-148.7)	Female	22	23.1	95.2	(59.6-144.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	8.2	73.5	(26.8-160.0)	Male	5	7.1	70.3	(22.7-164.1)
Female	3	7.1	nc	(nc-nc)	Female	4	6.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.2	nc	(nc-nc)	Male	13	24.3	53.6	(28.5-91.7)
Female	171	163.8	104.4	(89.3-121.3)	Female	23	21.2	108.3	(68.6-162.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	6.3	79.1	(25.5-184.5)	Male	19	16.7	114.0	(68.6-178.1)
<u>Colon / Rectum</u>					Female	14	8.3	168.4	(92.0-282.6)
Male	62	51.4	120.7	(92.5-154.7)	<u>Ovary</u>				
Female	57	55.4	102.8	(77.9-133.2)	Female	13	15.9	81.8	(43.5-139.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	12	11.1	108.1	(55.8-188.9)	Male	18	13.7	131.2	(77.7-207.3)
Female	1	3.4	nc	(nc-nc)	Female	10	15.9	63.0	(30.2-115.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	3.7	nc	(nc-nc)	Male	129	160.6	80.3	(67.1-95.5)
Female	3	3.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	11	9.8	111.8	(55.7-200.1)
Male	23	22.7	101.2	(64.1-151.9)	Female	4	6.4	nc	(nc-nc)
Female	13	13.8	94.1	(50.0-160.9)	<u>Testis</u>				
<u>Larynx</u>					Male	6	6.2	96.6	(35.3-210.4)
Male	6	6.4	93.3	(34.1-203.2)	<u>Thyroid</u>				
Female	1	1.9	nc	(nc-nc)	Male	3	9.1	nc	(nc-nc)
<u>Leukemia</u>					Female	29	29.2	99.2	(66.4-142.4)
Male	19	15.5	122.7	(73.8-191.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	20	12.3	162.6	(99.3-251.1)	Female	40	36.6	109.3	(78.1-148.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	8	12.3	65.2	(28.1-128.4)	Male	575	572.4	100.4	(92.4-109.0)
Female	0	4.5	nc	(nc-nc)	Female	608	581.8	104.5	(96.4-113.1)
<u>Lung and Bronchus</u>									
Male	100	78.7	127.1	(103.4-154.6)					
Female	98	83.7	117.1	(95.1-142.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Worcester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	169	169.7	99.6	(85.2-115.8)	Male	55	112.4	48.9	(36.9-63.7)
Female	69	67.3	102.6	(79.8-129.8)	Female	41	95.4	43.0	(30.8-58.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	30	34.2	87.7	(59.2-125.2)	Male	35	27.9	125.6	(87.4-174.6)
Female	32	30.1	106.5	(72.8-150.3)	Female	15	24.0	62.5	(34.9-103.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	6	4.9	121.5	(44.4-264.4)	Male	92	99.3	92.6	(74.7-113.6)
Female	551	647.3	85.1	(78.2-92.5)	Female	94	85.9	109.4	(88.4-133.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	42	25.9	162.1	(116.8-219.2)	Male	59	66.7	88.4	(67.3-114.1)
<u>Colon / Rectum</u>					Female	33	33.3	99.0	(68.1-139.0)
Male	197	205.9	95.7	(82.8-110.0)	<u>Ovary</u>				
Female	222	226.9	97.9	(85.4-111.6)	Female	70	64.2	109.0	(85.0-137.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	53	43.1	122.9	(92.0-160.7)	Male	47	54.3	86.6	(63.6-115.1)
Female	12	13.7	87.6	(45.2-153.1)	Female	54	64.6	83.6	(62.8-109.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	18	17.1	105.2	(62.3-166.3)	Male	516	610.4	84.5	(77.4-92.2)
Female	8	14.4	55.6	(24.0-109.6)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	44	39.4	111.7	(81.2-150.0)
Male	81	90.1	89.9	(71.4-111.7)	Female	33	26.6	123.9	(85.3-174.1)
Female	55	54.9	100.2	(75.5-130.5)	<u>Testis</u>				
<u>Larynx</u>					Male	29	29.2	99.3	(66.5-142.6)
Male	35	25.0	139.8	(97.3-194.4)	<u>Thyroid</u>				
Female	7	7.6	92.6	(37.1-190.9)	Male	39	37.8	103.2	(73.4-141.1)
<u>Leukemia</u>					Female	103	121.3	84.9	(69.3-103.0)
Male	52	64.6	80.5	(60.1-105.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	51	51.2	99.6	(74.2-131.0)	Female	171	144.3	118.5	(101.4-137.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	69	48.0	143.8	(111.9-181.9)	Male	2146	2263.4	94.8	(90.8-98.9)
Female	28	17.9	156.1	(103.7-225.6)	Female	2215	2339.7	94.7	(90.8-98.7)
<u>Lung and Bronchus</u>									
Male	359	305.1	117.7	(105.8-130.5)					
Female	357	328.5	108.7	(97.7-120.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Worthington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.7	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	7	5.6	124.9	(50.0-257.3)	Female	0	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	1	2.1	nc	(nc-nc)	<u>Ovary</u>				
Female	1	1.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	9	7.1	127.6	(58.2-242.2)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.0	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.3	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.5	nc	(nc-nc)	Male	19	23.7	80.0	(48.2-125.0)
Female	0	0.1	nc	(nc-nc)	Female	16	18.4	86.7	(49.5-140.8)
<u>Lung and Bronchus</u>									
Male	1	3.2	nc	(nc-nc)					
Female	2	2.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wrentham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	9.5	136.4	(72.6-233.3)	Male	8	7.3	110.1	(47.4-217.0)
Female	7	3.5	200.2	(80.2-412.5)	Female	9	5.8	156.3	(71.3-296.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.3	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	6.3	nc	(nc-nc)
Female	44	42.7	103.1	(74.9-138.4)	Female	1	4.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.7	nc	(nc-nc)	Male	4	5.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	5	2.0	250.3	(80.7-584.1)
Male	13	12.6	103.0	(54.8-176.2)	<u>Ovary</u>				
Female	19	11.9	159.5	(96.0-249.1)	Female	4	3.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	2.9	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	2	3.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.0	nc	(nc-nc)	Male	47	43.7	107.6	(79.0-143.1)
Female	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.3	nc	(nc-nc)
Male	2	6.2	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
Female	3	3.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.6	nc	(nc-nc)
Male	1	1.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	0.5	nc	(nc-nc)	Male	3	2.7	nc	(nc-nc)
<u>Leukemia</u>					Female	6	8.1	74.3	(27.1-161.8)
Male	3	3.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	2.8	253.1	(101.4-521.5)	Female	9	9.5	94.4	(43.1-179.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	3.5	nc	(nc-nc)	Male	141	146.6	96.2	(80.9-113.4)
Female	3	1.0	nc	(nc-nc)	Female	156	139.0	112.2	(95.3-131.3)
<u>Lung and Bronchus</u>									
Male	16	18.6	86.1	(49.2-139.9)					
Female	14	18.2	77.1	(42.1-129.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Yarmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	65	44.1	147.3	(113.7-187.8)	Male	56	25.5	219.7	(166.0-285.3)
Female	27	17.8	151.6	(99.9-220.6)	Female	45	19.6	229.8	(167.6-307.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	6.5	77.0	(24.8-179.7)	Male	11	6.9	159.3	(79.4-285.1)
Female	9	6.2	145.8	(66.5-276.7)	Female	8	6.3	127.4	(54.8-251.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.3	nc	(nc-nc)	Male	34	22.1	153.9	(106.5-215.0)
Female	173	148.8	116.2	(99.5-134.9)	Female	21	21.3	98.5	(61.0-150.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	4.6	130.8	(47.8-284.7)	Male	19	14.4	131.6	(79.2-205.5)
<u>Colon / Rectum</u>					Female	8	8.0	100.6	(43.3-198.2)
Male	57	49.9	114.2	(86.5-147.9)	<u>Ovary</u>				
Female	52	57.7	90.1	(67.3-118.2)	Female	18	15.0	120.3	(71.2-190.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	11	10.6	103.7	(51.7-185.6)	Male	20	13.8	144.6	(88.3-223.4)
Female	10	3.7	268.5	(128.5-493.8)	Female	20	17.1	117.2	(71.5-181.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	6	2.3	263.1	(96.1-572.7)	Male	202	152.5	132.5	(114.8-152.0)
Female	2	2.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	10	9.8	102.0	(48.8-187.6)
Male	18	20.5	88.0	(52.1-139.0)	Female	9	6.8	133.2	(60.8-252.8)
Female	14	13.5	103.4	(56.5-173.5)	<u>Testis</u>				
<u>Larynx</u>					Male	3	3.0	nc	(nc-nc)
Male	7	6.1	114.9	(46.0-236.7)	<u>Thyroid</u>				
Female	2	1.9	nc	(nc-nc)	Male	11	6.8	162.8	(81.1-291.3)
<u>Leukemia</u>					Female	10	20.1	49.7	(23.8-91.4)
Male	21	14.5	144.5	(89.4-220.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	14	11.9	117.3	(64.1-196.9)	Female	33	34.3	96.1	(66.1-135.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	10	10.9	91.4	(43.8-168.2)	Male	721	543.1	132.8	(123.2-142.8)
Female	2	4.5	nc	(nc-nc)	Female	644	558.0	115.4	(106.7-124.7)
<u>Lung and Bronchus</u>									
Male	100	79.1	126.5	(102.9-153.9)					
Female	104	89.1	116.8	(95.4-141.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;